CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The healthcare stock market has garnered copies amounts of media attention over the course of the past few years, as more people have come to understand the variety of benefits of introducing cannabis as a means of treatment for a myriad of ailments. Over time, in an effort to further these advancements in the healthcare industry, legislators have sought to pass positive legislation in favor of legalizing marijuana, resulting in the passing of the US Farm Bill as well as other laws around the world. Medical experts and healthcare professionals have begun to take cannabis mores seriously as a form of treatment, given its incredible abilities as an anti-inflammatory, as well as other medicinal benefits, and in turn, this has catalyzed significant investor excitement for individuals looking for potential opportunities in the space. Premier Health Group (OTC: PHGRF) (CSE: PHGI), Can-Fite BioPharma Ltd (NYSE: CANF), BioLineRx Ltd (NASDAQ: BLRX), and Aurora Cannabis Inc., (NYSE: ACB) represent four cannabis companies determined to develop nuanced approaches for integrating cannabis as a means for improving the quality of life for consumers.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's commitment to developing and distributing the best quality products and services meant to improve the lives of their patients.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced last week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.
Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, ''We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking, and other premium services with our electronic medical records (EMR) system.''
For More Information On Premier Health Group, Click Here
Can-Fit BioPharma Ltd (CANF), a biotechnology company working to advance a pipeline of small molecular drugs that address cancer, live and inflammatory diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, ''Use of A3 adenosine receptor agonist in the treatment of Osteoarthritis." This patent addresses methods for treating osteoarthritis with A3 adenosine receptor (A3AR) agonists and has been granted to Can-Fite in major global markets including North and South America, Europe and Asia.
Following the announcement, Dr. Ilan Cohn, the Company's Chairman of the Board, said, ''the notice of allowance for this patent application is designed to secure Can-Fite's proprietary rights in a commercially very important and lucrative therapeutic indication. This new patent application adds significant value to Can-Fite's very extensive and valuable patent estate and may provide the platform for developing Can-Fite's proprietary A3AR agonists for osteoarthritis, where there is a market need for efficacious and safe drugs.''
For More Information On Can-Fite BioPharma Ltd, Click Here
BioLineRx Ltd (BLTX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040, for the treatment of pancreatic cancer.
Philip Serlin, Chief Executive Officer of BioLineRx, commented, ''despite advances in the treatment of various cancers with immune checkpoint inhibitors, pancreatic cancer is refractory to these treatment options, and remains an area of significant unmet medical need. We have previously reported encouraging clinical data supporting the potential of BL-8040 as part of an immunotherapy combination treatment in pancreatic cancer, and we look forward to top-line results from our ongoing pancreatic clinical studies later this year.
For More Information on BioLineRx Ltd, Click Here
Aurora Cannabis Inc (ACB) today announced that its extraction technology partner, Radient Technologies, has received its Standard Processing License from Health Canada. Back in 2016, Aurora considered Radient's operations to be potentially harmful to the cannabis industry because of their ability to achieve higher throughputs than was possible with bench marking tech at the time, resulting in Aurora's decision to invest in the Company.
Terry Booth, Aurora's CEO, stated that ''Early on we identified that the ability to extract cannabis and hemp at large-scale while preserving quality would be a crucial competitive advantage to address the rapidly growing market for derivative products, such as vapes pen solutions, softgels, edibles, and beverages. With the upcoming new regulations permitting additional form factors and Radient's recent receipt of its processor license, we are in a strong position to rapidly expand production of a broad portfolio of extract-based products, tying in well with the significant scale-up of our global cannabis and hemp operations.''
For More Information On Aurora Cannabis Inc., Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc., we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
CONTACT:
SOURCE: Stock Price